<DOC>
	<DOCNO>NCT00543491</DOCNO>
	<brief_summary>This study assess MK0767 's ability vs. placebo control blood glucose patient type 2 diabetes gauge whether fast blood glucose lower , blood fat improve , insulin level impact . This early phase trial specific protocol information progress publicly available time . ( Full information available trial participant ) .</brief_summary>
	<brief_title>MK0767 Sulfonylurea Combination Study ( 0767-027 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 Diabetes inadequate glycemic control On Sulfonylurea monotherapy Male nonpregnant Females Age 21 78 year , inclusive On stable dose sulfonylurea least 2 week prior Visit 2/Week6 History Type 1 diabetes Patient currently insulin ( monotherapy combination oral agent ) , Rosiglitazone pioglitazone PPARy agonist , Metformin agents Patients history intolerance PPARy agonist</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>